OCT 22·SEC EDGARLow
Epstein David R purchased $89K of AGMB
Epstein David R purchased 10,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.88 ($8.86–$8.90) across 2 trades on 2026-10-21.
StockNASDAQ · US · USDHealthcare · BIOTECHNOLOGY
$AGMB
AgomAb Therapeutics NV
Price · $AGMBvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $AGMB in the last 7 days.
Insider · 30dAll trades →
- Buys
- $400K 10 txs
- Sells
- — 0 txs
Epstein David R5× · $220K
10b5-1 share of filings0%
Top stories · $AGMBMore →
OCT 21·investing.com
Agomab Therapeutics stock rating reiterated at Buy by H.C. Wainwright
H.C. Wainwright reiterated a Buy rating and $35 price target for Agomab Therapeutics (AGMB) after a panel discussion at United European Gastroenterology Week. The stock trades at $8.73, with potential upside of over 300%. Analysts highlight the company's financial strength and the potential of its drug ontunisertib for fibrostenosing Crohn’s disease. Other analysts have also initiated coverage with positive ratings and price targets.
OCT 13·tipranks.com
Agomab Doses First Patient in Global Phase 2b NOV-ERA Trial for Fibrostenosing Crohn’s Disease
Agomab Therapeutics (AGMB) dosed the first patient in its global Phase 2b NOV-ERA trial for fibrostenosing Crohn’s disease. The study will enroll 320 adults to evaluate ontunisertib over 52 weeks, with a primary endpoint at Week 24. The trial follows positive Phase 2a data and triggers a €7 million milestone payment. AGMB has a Buy rating and $28 price target from analysts.
AGMB sentiment & insider activity
Recent AGMB coverage spans insider activity, financial news and technology.
In the last 30 days, AGMB insiders filed 10 SEC Form 4 transactions — 10 purchases ($400K) and no sales. The most active reporter was Epstein David R with 5 filings.
What's driving AGMB
The insider purchase signals confidence from a board member, but the transaction size is modest.
Analyst upgrade with a high price target may drive buying interest.
The trial start is a material clinical milestone that could lift the stock if data remain positive.
Small insider purchase may signal modest confidence but size is negligible for price.
Agomab Therapeutics will present Phase 2a STENOVA trial data on ontunisertib for Fibrostenosing Crohn’s disease at UEG Week 2026. The open-label extension results support the initiation of the global NOV-ERA Phase 2b study. Agomab will also host a symposium on fibro-inflammation in IBD. Ontunisertib is an investigational drug designed to inhibit ALK5/TGF-β in the GI tract.
AlphAI scores every news story that mentions AGMB with an AI model for sentiment and relevance, and aggregates insider trades from AgomAb Therapeutics NV's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $AGMB
Score
Epstein David R purchased $89K of AGMB
Epstein David R purchased 10,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.88 ($8.86–$8.90) across 2 trades on 2026-10-21.
1 min readAgomab Therapeutics stock rating reiterated at Buy by H.C. Wainwright
H.C. Wainwright reiterated a Buy rating and $35 price target for Agomab Therapeutics (AGMB) after a panel discussion at United European Gastroenterology Week. The stock trades at $8.73, with potential upside of over 300%. Analysts highlight the company's financial strength and the potential of its drug ontunisertib for fibrostenosing Crohn’s disease. Other analysts have also initiated coverage with positive ratings and price targets.
2 min readAgomab Doses First Patient in Global Phase 2b NOV-ERA Trial for Fibrostenosing Crohn’s Disease
Agomab Therapeutics (AGMB) dosed the first patient in its global Phase 2b NOV-ERA trial for fibrostenosing Crohn’s disease. The study will enroll 320 adults to evaluate ontunisertib over 52 weeks, with a primary endpoint at Week 24. The trial follows positive Phase 2a data and triggers a €7 million milestone payment. AGMB has a Buy rating and $28 price target from analysts.
1 min readEpstein David R purchased $44K of AGMB
Epstein David R purchased 5,000 shares of AgomAb Therapeutics NV (AGMB) at $8.90 on 2026-10-08.
1 min readAgomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
Agomab Therapeutics will present Phase 2a STENOVA trial data on ontunisertib for Fibrostenosing Crohn’s disease at UEG Week 2026. The open-label extension results support the initiation of the global NOV-ERA Phase 2b study. Agomab will also host a symposium on fibro-inflammation in IBD. Ontunisertib is an investigational drug designed to inhibit ALK5/TGF-β in the GI tract.
2 min readEpstein David R purchased $86K of AGMB
Epstein David R purchased 10,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.64 ($8.57–$8.70) across 2 trades over 2026-10-05 to 2026-10-06.
1 min readKemula Pierre Thadee Victor purchased $86K of AGMB
Kemula Pierre Thadee Victor (Chief Financial Officer) purchased 10,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.59 ($8.54–$8.67) across 3 trades on 2026-10-06.
1 min readKnotnerus Tim Jasper purchased $94K of AGMB
Knotnerus Tim Jasper (Chief Executive Officer) purchased 11,000 shares of AgomAb Therapeutics NV (AGMB) at an average of $8.58 ($8.48–$8.70) across 2 trades over 2026-10-05 to 2026-10-06.
1 min readH.C. Wainwright reiterates Agomab stock rating on trial data
H.C. Wainwright reiterated a Buy rating and $35 price target on Agomab Therapeutics (AGMB) after positive Phase 2a STENOVA trial data. The stock is near its 52-week low, down 18% in a week. Analysts' price targets range from $28 to $60. Agomab has no debt and holds more cash, providing financial flexibility. Piper Sandler and B. Riley also initiated coverage with positive ratings and targets of $60 and $34, respectively.
2 min readWhy is Agomab Therapeutics stock sliding today?
Agomab Therapeutics (AGMB) shares fell 6.1% despite positive 60-week trial data for ontunisertib, showing sustained disease control in Crohn’s patients. The decline followed a pre-market gain and a downgrade to 'Sell' by Wall Street Zen. The stock's 52-week range is $8.75 to $17.82, with a current price of $10.43, below the consensus target.
2 min read